Research

Dr. Oh brings extensive expertise in preclinical development and translational research of CAR-T cell therapies, with a strong focus on both B cell malignancies and B cell-mediated autoimmune diseases. Over the past five years, Dr. Oh has published nine peer-reviewed articles, including three as first or co-first author in high-impact journals—Nature Biotechnology (2023), Science Advances (2025), and Immune Network (2022)—all of which directly relate to the development and application of CAR-T cell platforms.

Dr. Oh has made significant contributions to the field of autoimmune CAR-T therapy by developing a novel chimeric autoantibody receptor T (CAAR-T) platform that selectively targets autoantibody-producing B cells without affecting healthy immune cells. This approach led to the development of MuSK-CAART, currently in clinical trials (NCT05451212), following successful technology transfer and patent licensing. Two international patent applications have been filed, including one already granted in the United States.

In addition to autoimmune disease models, Dr. Oh has extensive experience in constructing and utilizing both syngeneic and xenograft (NSG) mouse models to evaluate CAR-T cell efficacy. These models have been instrumental in studying therapeutic responses in CD19⁺ B cell malignancies as well as autoantibody-driven autoimmune diseases, providing a robust platform for the in vivo validation of CAR-T and iCAR constructs. Dr. Oh has also participated in several high-profile CAR-T collaborative studies published in journals such as Nature (2024) and The Journal of Clinical Investigation (2020).